| Mr Orrin Blake Hansen, APRN | |
|
1175 E 50 S Ste 241, American Fork, UT 84003-2849 | |
| (801) 492-5999 | |
| (801) 418-0897 |
| Full Name | Mr Orrin Blake Hansen |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 20 Years |
| Location | 1175 E 50 S Ste 241, American Fork, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104916543 | NPI | - | NPPES |
| 1104916543 | Medicaid | UT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 282878-4405 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Utah Clinic Pc | 7517868508 | 391 |
News Archive
Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.
A team led by Michael Trauner at MedUni Vienna's Division of Gastroenterology and Hepatology demonstrated the beneficial effect of synthetically produced bile acid with the active agent nor-ursodeoxycholic acid (nor-urso) in the hitherto incurable liver disease primary sclerosing cholangitis (PSC) around two years ago.
Spherix Incorporated has announced that it has begun its Phase 3 clinical trial of Naturlose as a treatment for Type 2 diabetes.
Liberator Medical Holdings, Inc. today pre-announces record net revenues of approximately $7.7 million for its fiscal fourth quarter ended September 30, 2009, representing an annualized revenue run rate of over $30.0 million.
Rates of C. difficile infections have decreased 36% in hospitals across Canada, although the virulent NAP1 strain associated with severe illness and deaths is the most common strain, according to research published in CMAJ.
› Verified 8 days ago
| Entity Name | Central Utah Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093764805 PECOS PAC ID: 7517868508 Enrollment ID: O20040113000805 |
News Archive
Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.
A team led by Michael Trauner at MedUni Vienna's Division of Gastroenterology and Hepatology demonstrated the beneficial effect of synthetically produced bile acid with the active agent nor-ursodeoxycholic acid (nor-urso) in the hitherto incurable liver disease primary sclerosing cholangitis (PSC) around two years ago.
Spherix Incorporated has announced that it has begun its Phase 3 clinical trial of Naturlose as a treatment for Type 2 diabetes.
Liberator Medical Holdings, Inc. today pre-announces record net revenues of approximately $7.7 million for its fiscal fourth quarter ended September 30, 2009, representing an annualized revenue run rate of over $30.0 million.
Rates of C. difficile infections have decreased 36% in hospitals across Canada, although the virulent NAP1 strain associated with severe illness and deaths is the most common strain, according to research published in CMAJ.
› Verified 8 days ago
| Entity Name | Physician Group Of Utah Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477676930 PECOS PAC ID: 8022032234 Enrollment ID: O20060113000886 |
News Archive
Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.
A team led by Michael Trauner at MedUni Vienna's Division of Gastroenterology and Hepatology demonstrated the beneficial effect of synthetically produced bile acid with the active agent nor-ursodeoxycholic acid (nor-urso) in the hitherto incurable liver disease primary sclerosing cholangitis (PSC) around two years ago.
Spherix Incorporated has announced that it has begun its Phase 3 clinical trial of Naturlose as a treatment for Type 2 diabetes.
Liberator Medical Holdings, Inc. today pre-announces record net revenues of approximately $7.7 million for its fiscal fourth quarter ended September 30, 2009, representing an annualized revenue run rate of over $30.0 million.
Rates of C. difficile infections have decreased 36% in hospitals across Canada, although the virulent NAP1 strain associated with severe illness and deaths is the most common strain, according to research published in CMAJ.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Orrin Blake Hansen, APRN 1055 N 500 W, Att Credentialing, Provo, UT 84604 Ph: (801) 543-8225 | Mr Orrin Blake Hansen, APRN 1175 E 50 S Ste 241, American Fork, UT 84003-2849 Ph: (801) 492-5999 |
News Archive
Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.
A team led by Michael Trauner at MedUni Vienna's Division of Gastroenterology and Hepatology demonstrated the beneficial effect of synthetically produced bile acid with the active agent nor-ursodeoxycholic acid (nor-urso) in the hitherto incurable liver disease primary sclerosing cholangitis (PSC) around two years ago.
Spherix Incorporated has announced that it has begun its Phase 3 clinical trial of Naturlose as a treatment for Type 2 diabetes.
Liberator Medical Holdings, Inc. today pre-announces record net revenues of approximately $7.7 million for its fiscal fourth quarter ended September 30, 2009, representing an annualized revenue run rate of over $30.0 million.
Rates of C. difficile infections have decreased 36% in hospitals across Canada, although the virulent NAP1 strain associated with severe illness and deaths is the most common strain, according to research published in CMAJ.
› Verified 8 days ago
Andrew Olesen, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 922 Nob Hill Ave, American Fork, UT 84003 Phone: 801-471-0951 | |
Sandra Burkinshaw, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1248 E 90 N, Suite 300, American Fork, UT 84003 Phone: 801-756-9635 | |
Sarah Prentice, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 226 N 1100 E, American Fork, UT 84003 Phone: 801-855-3841 | |
Joseph Woodruff Palmer, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1175 E 50 S Ste 171, American Fork, UT 84003 Phone: 801-772-0698 Fax: 801-772-0705 | |
Hayley Alece Jolley, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1248 E 90 N Ste 103, American Fork, UT 84003 Phone: 801-852-9560 | |
Mr. Todd L Chidester, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1159 E 200 N Suite 200, American Fork, UT 84003 Phone: 801-756-5290 Fax: 801-756-5200 |